OncoZenge
3.89 SEK -9.43%Be the first to follow this company
OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ONCOZ
Daily low / high price
3.8 / 4.04
SEK
Market cap
45.56M SEK
Turnover
298.02K SEK
Volume
75K
Financial calendar
Interim report
2024-05-21
General meeting
2024-05-31
Interim report
2024-08-27
Interim report
2024-11-26
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Niclas Holmgren | 10.9 % | 10.9 % |
Linc AB | 10.0 % | 10.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
OncoZenge AB: OncoZenge publicerar rapport om BupiZenge™ och otillfredsställda medicinska behov
OncoZenge AB: OncoZenge Appoints Åsa Nilsson as Clinical Research Manager
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools